JNJ
The long game is looking pretty good
Johnson & Johnson is back with more CARVYKTI bragging rights, and this one has some staying power. The company says a single infusion of ciltacabtagene autoleucel delivered five-year treatment-free remissions in 50% of patients with early-line relapsed/refractory multiple myeloma.
Why investors should care
That’s not just a nice-sounding clinical update. In cancer drugs, durability is the whole ballgame — if a therapy can keep patients off treatment for years, it can justify premium pricing, support adoption, and make the drug feel a lot less like a one-hit wonder.
- CARVYKTI already matters in J&J’s oncology lineup, and these long-term data help extend the runway.
- Five-year treatment-free remission is the kind of result that can shift how doctors think about sequencing therapy.
- For shareholders, it adds more evidence that J&J’s growth story still has some juice even as older blockbuster franchises face more pressure.
Big picture
This is the medical equivalent of a sequel that doesn’t stink. The longer CARVYKTI can keep patients in remission without constant re-treatment, the more valuable the asset becomes — and the more J&J can lean on it as a future growth engine.